Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Hes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (E2F1 ChIP-seq)

ABSTRACT: Hes6 is a transcription co-factor that is associated with stem cell characteristics in neural tissue, but its role in cancer remains uncertain. Here we show that Hes6 is controlled by c-Myc and the AR and can drive castration resistance in xenografts of the androgen-dependent LNCaP prostate cancer cell line model. Hes6 activates a cell cycle enhancing transcriptional network that maintains tumour growth in the absence of circulating androgen but with maintained nuclear AR. We demonstrate interaction between E2F1, the AR and Hes6 and show the co-dependency of these factors in the castration-resistant setting. In the clinical setting, we have discovered a Hes6-associated signature that predicts poor outcome in prostate cancer, which could be pharmacologically targeted. E2F1 ChIPseq on LNCaP cells.

ORGANISM(S): Homo sapiens

SUBMITTER: Roslin Russell 

PROVIDER: E-GEOD-36614 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml
altmetric image

Publications

Castrate-resistant prostate cancer (CRPC) is poorly characterized and heterogeneous and while the androgen receptor (AR) is of singular importance, other factors such as c-Myc and the E2F family also play a role in later stage disease. HES6 is a transcription co-factor associated with stem cell characteristics in neural tissue. Here we show that HES6 is up-regulated in aggressive human prostate cancer and drives castration-resistant tumour growth in the absence of ligand binding by enhancing the  ...[more]

Similar Datasets

Genomics Hes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (cMyc ChIP-seq)
2014-04-17 | E-GEOD-37617 | biostudies-arrayexpress
Unknown Hes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (E2F1 ChIP-seq)
2014-04-17 | GSE36614 | GEO
Transcriptomics Hes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (LNCaP)
2014-04-17 | E-GEOD-36434 | biostudies-arrayexpress
Transcriptomics Hes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (xenografts)
2014-04-17 | E-GEOD-36433 | biostudies-arrayexpress
Unknown Hes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (LNCaP)
2014-04-17 | GSE36434 | GEO
Unknown Hes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (xenografts)
2014-04-17 | GSE36433 | GEO
Unknown Hes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (cMyc ChIP-seq)
2014-04-17 | GSE37617 | GEO
Genomics Hes6 drives a critical AR transcriptional program to induce castration resistant prostate cancer through activation of an E2F1-mediated cell cycle network
2014-04-17 | E-GEOD-49832 | biostudies-arrayexpress
Unknown Hes6 drives a critical AR transcriptional program to induce castration resistant prostate cancer through activation of an E2F1-mediated cell cycle network
2014-04-17 | GSE49832 | GEO
Transcriptomics Hes6 drives a network with therapeutic potential in castrate-resistant prostate cancer
2014-04-17 | E-GEOD-36526 | biostudies-arrayexpress